FDA Drug Approval Summaries: Fulvestrant

Patients with hormone‐sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy. Fulvestrant (Faslodex®, ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2002-01, Vol.7 (6), p.477-480
Hauptverfasser:	Bross, Peter F., Cohen, Martin H., Williams, Grant A., Pazdur, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Breast cancer Breast Neoplasms - drug therapy Drug Approval Estradiol - analogs & derivatives Estradiol - therapeutic use Female Fulvestrant Hormone therapy Humans Metastatic Postmenopause Randomized Controlled Trials as Topic Survival Rate Treatment Outcome United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!